Anti-Human C5 (Eculizumab)

Human C5

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Eculizumab. Clone 5G1.1 binds with high affinity and specificity to the complement protein C5.

Complement component 5 (C5) is a crucial protein in the complement system, part of the body’s immune response. It is synthesized in the liver and circulates in the blood as an inactive precursor. When triggered, C5 splits into C5a and C5b. C5a acts as an inflammation promoter and attracts immune cells to infection sites. C5b kickstarts the creation of the membrane attack complex (MAC), which creates pores in the membranes of pathogens, leading to their destruction. Irregularities in C5 activation are linked to illnesses such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)^1,2.

The clone 5G1.1, also known as Eculizumab, is a humanized monoclonal antibody designed to target the complement protein C5. Binding to C5 prevents its cleavage into C5a and C5b, thereby blocking the formation of the membrane attack complex (MAC). This inhibition is essential for reducing the inflammatory and cell-lysing effects that come with complement activation. Eculizumab has received approval for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), both of which are rare, life-threatening conditions resulting from uncontrolled complement activation. Its effectiveness in these disorders has established it as a pioneering treatment in immunology^3-9.

The complement component C5 is primarily found in the plasma and extracellular matrix. It is synthesized in the liver and then secreted into the bloodstream.

1. Fredslund F, Laursen NS, Roversi P, et al. Nat Immunol. 2008;9(7):753-760.
2. C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease - PubMed. Accessed August 11, 2024. https://pubmed.ncbi.nlm.nih.gov/34321906/
3. Wong EKS, Kavanagh D. Transl Res. 2015;165(2):306-320.
4. Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. J Nephrol. 2019;32(1):17-25.
5. Merrill SA, Brodsky RA.Hematology Am Soc Hematol Educ Program. 2018;2018(1):371-376.
6. McKeage K. Drugs. 2011;71(17):2327-2345.
7. Keating GM. Drugs. 2013;73(18):2053-2066.
8. Diamante Chiodini B, Davin JC, Corazza F, et al. Pediatrics. 2014;133(6):e1764-1768.
9. Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship THJ. Immunobiology.2016;221(6):715-718.
10. Eculizumab Monoclonal Antibody (4F6), GenScript - Antibodies, Primary Antibodies. Accessed August 8, 2024. https://www.fishersci.com/shop/products/eculizumab-monoclonal-antibody-4f6-genscript/502530049
11. Mouse Anti-C5 Recombinant Antibody (clone m5G1.1) - Creative Biolabs. Accessed August 8, 2024. https://www.creativebiolabs.net/Anti-C5-Recombinant-Antibody-clone-m5G1-1-75875.htm
12. ECULI - Overview: Eculizumab, Serum. Accessed August 11, 2024. https://www.mayocliniclabs.com/test-catalog/Overview/65676